A Trial Evaluating Concurrent Whole Brain Radiotherapy and Iniparib in Multiple Non Operable Brain Metastases

Inclusion Criteria: * Non operable brain metastases from any type of cancer (≥ 2) * At least one measured brain target available ≥ 1 cm (T1-weighted sequences with contrast application MRI) * No stereotaxie indication * Any anterior treatments for systemic disease (any chemotherapy at any line) are accepted but have to be interrupted at least 15 days before and up to 30 days after the present protocol * No extra-brain disease or stabilized since at least 1 month * Aged ≥ 18 years old * KPS \> 70 (RPS class I or II) * Adequate bone marrow function: WBC ≥ 3.5 x 109/L, ANC ≥ 1.5 x 109/L, Platelets ≥ LLN, Hb \> 10g/dL, * Adequate renal function: serum creatinine ≤ 1.5 × ULN and blood urea nitrogen ≤ 25 mg/dL * Male or female patient using adequate contraceptive method * Women of childbearing potential must have a negative serum or urine pregnancy test within 3 days prior to the start of treatment * Informed and signed consent * Able to be followed according to the terms of the protocol * Affiliated to the French National social security Exclusion Criteria: * Anterior treatment for brain metastases (surgery, radiosurgery, stereotaxie) * Leptomeningeal metastases * Inclusion in another protocol within 30 days * Brain metastases with severe intracranial hypertension clinical signs * Other cancer except the known primary tumor or in situ cervix cancer or basocellular carcinoma